Annenberg Center for Health Sciences At Eisenhower’s Post

CU Cancer Center leader Christopher Lieu, MD, discusses how immunotherapy has changed the landscape for the treatment of metastatic hepatocellular carcinoma with Namrata Vijayvergia, MD, of Fox Chase Cancer Center. Watch the discussion here: https://bit.ly/3vI0zXY #Carcinoma #Immunotherapy #CancerTreatment

In this interview, Alex Spira, MD, PhD, FACP, FASCO, discussed post-progression results from the phase 3 MARIPOSA-2 trial, which showed that amivantamab plus chemotherapy prolonged time to treatment discontinuation and time to subsequent therapy in patients with EGFR-mutated NSCLC. "We believe this will present a new standard after disease progression on osimertinib," said Dr Spira. Check out the full video here: https://lnkd.in/ebVwQnuu #JournalOfClinicalPathways #NonSmallCellLungCancer #NSCLC #ClinicalTrial 

Want to stay up-to-date with what is going on? Follow our Page for the latest updates on #ovariancancer treatment options, #clinicaltrials and More

🌸 October marks the beginning of Breast Cancer Awareness Month around the World! This month serves as a crucial reminder of the importance of early screening and access to care. Having worked as a pharmaceutical representative and Patient Journey Partner, I witnessed firsthand the challenges patients face in obtaining timely diagnoses. Time is very important! Seeing special friends battle this disease is truly heartbreaking, which is why early detection is so important.That makes the difference! When was the last time you performed a self-examination? Prevention is key—today is the perfect time to prioritize your health! #BreastCancerAwarenessMonth #EarlyDetection #Support #HealthCare

Our Medical Director, Rahul Nawander MD, FALU, FLMI, will be presenting at the 2024 Midwestern Underwriting Conference tomorrow! His presentation will provide a comprehensive overview of the evolving landscape of metastatic melanoma, encompassing global epidemiological shifts, groundbreaking immunotherapy advancements, and remarkable improvements in patient survival rates witnessed over recent decades. By examining the transformative impact of novel treatment strategies, particularly immunotherapy medications, it elucidates the unprecedented opportunities for achieving long-term remission and possibly, a road to cure for metastatic melanoma. Through a forward-looking lens, the presentation explores the ongoing journey toward conquering this formidable disease, offering insights into the future of melanoma treatment and the pursuit of a definitive "road to cure." We hope to see you there! #FasanoUnderwriting #MetastaticMelanoma #Immunotherapy

Today is Mesothelioma Awareness Day. Malignant pleural mesothelioma (MPM) is rare and amongst the most aggressive and lethal cancers, caused primarily by asbestos exposure. The UK has the highest prevalence of mesothelioma cases in the world, with approximately 2,700 people diagnosed with the cancer each year. Due to the aggressive nature of mesothelioma, treatment options are limited. As a global clinical research organisation (CRO), TMC completed a pivotal Phase 2 clinical trial in patients with MPM. We supported successful patient enrolment, recruiting patients over a 24-month period and enabling 344 patients to participate across 74 sites worldwide.  Read the full case study below. #Mesothelioma #MesotheliomaAwarenessDay #RareCancer #ClinicalTrial #CaseStudy

Today at #GI24 we announce positive results from the EMERALD-1 Phase III trial evaluating patients with hepatocellular carcinoma (#HCC) eligible for embolization. Most patients in this setting experience high rates of disease progression even after receiving the current standard of care. Read more to discover how #immunotherapy could help patients diagnosed with earlier stages of #LiverCancer: https://learn.az/6046rvU0i #AZUS

By prioritizing patient-centered care and fostering ongoing research, we can collectively transform #cancer survivorship and empower individuals to lead fulfilling lives beyond their diagnosis. Awny Farajallah, MD, FACP, Chief Medical Officer, Global Oncology, explains how the future of cancer care is rooted in prioritizing an individual's overall well-being. Read more: https://lnkd.in/gsVnpzu5

Join Thomas Powles, MD @tompowles1, as we discuss the groundbreaking Enfortumab Vedotin and Pembrolizumab combo for #BladderCancer. Achieving a remarkable 53% risk reduction in mortality. Watch the exclusive interview [video]:https://bit.ly/46Mt3gA

Pharmacists' role in community-based cancer care continues to expand, which makes more multidisciplinary care available to patients. According to Regional Cancer Care Associates's Tom Ollis, MS, RPh, pharmacists can bring significant insight into important areas, such as: 💊 Navigating drug shortages 💊 Evaluating and integrating new agents 💊 Mitigating adverse effects 💊 Gathering and sharing important information 💊 Helping to provide better overall care Find out more in this article from Pharmacy Times: https://lnkd.in/gz-RgNTX #Pharmacists #CommunityCare #LocalCancerCare